## Kenneth R Carson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1183433/publications.pdf

Version: 2024-02-01

471509 454955 2,254 36 17 30 citations h-index g-index papers 37 37 37 3256 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	1
2	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	1
3	Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin Lymphoma. Journal of Geriatric Oncology, 2020, 11, 69-74.	1.0	14
4	Venous thromboembolism in multiple myeloma is associated with increased mortality. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1203-1210.	2.3	19
5	Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 744-748.	0.4	8
6	Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. American Journal of Hematology, 2019, 94, 1176-1184.	4.1	112
7	Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma. EBioMedicine, 2019, 46, 170-183.	6.1	26
8	The role of autologous stem cell transplantation in patients with nodal peripheral Tâ€cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer, 2019, 125, 1507-1517.	4.1	106
9	Progressive multiâ€focal leucoencephalopathy among ibrutinibâ€treated persons with chronic lymphocytic leukaemia. British Journal of Haematology, 2018, 180, 301-304.	2.5	16
10	Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study. Journal of the National Cancer Institute, 2017, 109, djw264.	6.3	61
11	Reply to S. Suissa et al. Journal of Clinical Oncology, 2017, 35, 1378-1379.	1.6	O
12	A phase <scp>II</scp> study of cyclophosphamide, etoposide, vincristine and prednisone ( <scp>CEOP</scp> ) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral Tâ€cell lymphoma ( <scp>PTCL</scp> ): final results from the Tâ€cell consortium trial. British Journal of Haematology, 2016, 172, 535-544.	2.5	71
13	Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data. Journal of Medical Economics, 2016, 19, 965-972.	2.1	8
14	Statins Are Associated With Reduced Mortality in Multiple Myeloma. Journal of Clinical Oncology, 2016, 34, 4008-4014.	1.6	76
15	Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria. Leukemia and Lymphoma, 2016, 57, 1191-1193.	1.3	18
16	Outcomes of Chemotherapy Treatment in Elderly Patients with Hodgkin Lymphoma. Blood, 2016, 128, 3545-3545.	1.4	2
17	Variability in the Practice of Fertility Preservation for Patients with Cancer. PLoS ONE, 2015, 10, e0127335.	2.5	10
18	Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. Journal of Geriatric Oncology, 2015, 6, 211-218.	1.0	47

#	Article	IF	CITATIONS
19	Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data. Thrombosis Research, 2015, 135, 616-620.	1.7	<b>7</b> 5
20	Expression of helper T cell master regulators in inflammatory dermatoses and primary cutaneous T-cell lymphomas: Diagnostic implications. Journal of the American Academy of Dermatology, 2015, 72, 159-167.	1.2	39
21	Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing. Blood, 2015, 126, 574-574.	1.4	2
22	Statin Therapy Improves Multiple Myeloma (MM) Specific Surviva. Blood, 2015, 126, 879-879.	1.4	0
23	Surveillance Imaging for Lymphoma: Pros and Cons. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e388-e395.	3.8	11
24	Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer, 2014, 120, 2464-2471.	4.1	113
25	Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL). Blood, 2014, 124, 4434-4434.	1.4	6
26	Rituximab-Associated Progressive Multifocal Leukoencephalopathy (PML) in HIV-Negative Patients: An Updated Report of 231 Confirmed Cases from the Southern Network on Adverse Reactions (SONAR)/Washington University Collaboration (2000-2012). Blood, 2014, 124, 4456-4456.	1.4	2
27	Influence of Body Mass Index on Survival in Veterans With Multiple Myeloma. Oncologist, 2013, 18, 1074-1079.	3.7	36
28	Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium. Blood, 2013, 122, 3032-3032.	1.4	11
29	Zoledronic Acid Improves Overall Survival Compared To Pamidronate In Multiple Myeloma. Blood, 2013, 122, 3182-3182.	1.4	0
30	Clinical and Economic Burden Of Peripheral T-Cell Lymphoma In The United States. Blood, 2013, 122, 2963-2963.	1.4	0
31	Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients. Blood, 2013, 122, 1785-1785.	1.4	0
32	Psoas Cross-Sectional Area As Radiographic Measure Of Sarcopenia Does Not Predict Overall Survival In Multiple Myeloma. Blood, 2013, 122, 5326-5326.	1.4	2
33	Increased Body Mass Index Is Associated With Improved Survival in United States Veterans With Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2012, 30, 3217-3222.	1.6	78
34	Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating. Leukemia and Lymphoma, 2009, 50, 323-324.	1.3	20
35	Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncology, The, 2009, 10, 816-824.	10.7	433
36	Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood, 2009, 113, 4834-4840.	1.4	829

3